In past years therapy has evolved, especially for cancers with known oncogenic driver mutations such as EGFR, ALK, ROS1 and BRAF, or newly discovered NSCLC drivers such as MET, RET, NTRK1/2/3 and ERBB2 (HER2). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.